- Sanofi reported strong Q3 results.
- Sanofi raised full-year guidance.
- Dupixent accounted for about half of the sales beat vs consensus.
Sanofi reported strong Q3 results and raised full-year guidance. J.P. Morgan says Dupixent drove half the sales beat; vaccines also beat consensus. New guidance could drive 3-5% consensus upgrades.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.